Comparative Effectiveness of Outpatient COVID‐19 Therapies in Solid Organ Transplant Recipients
Outpatient COVID-19 therapies were largely associated with improved outcomes among SOT recipients. These treatment agents showed similar rates of 30-day hospitalization, except for remdesivir. The choice of outpatient COVID-19 therapy in SOT recipients should primarily account for patients' individual circumstances and drug-drug interactions rather than differential therapeutic efficacy.
Authors
- Raymund Rabe Razonable (ORCID: https://orcid.org/0000-0001-5248-0227)
- David A. Helfinstine (ORCID: https://orcid.org/0000-0001-9532-7601)
- Viengneesee Thao (ORCID: https://orcid.org/0000-0003-2136-3540)
- Zachary A. Yetmar (ORCID: https://orcid.org/0000-0003-2098-2868)
- Kelly M. Pennington (ORCID: https://orcid.org/0000-0003-1187-5059)
Institutions
- Cleveland Clinic (US)
- Mayo Clinic (US)
- Optum (United States) (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Transplant Infectious Disease
- Published
- 2025-01-10
- DOI
- https://doi.org/10.1111/tid.14436
- Citations
- 1
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.40
Funders
- Mayo Clinic